WEE1 and Unclassified Renal Cell Carcinoma: The identification of this NF2 loss subset of uRCC provides an opportunity to improve our diagnosis of this particularly aggressive subset of tumours, and test new therapeutic strategies such as those aimed at interfering with YAP activity54, or the synthetic lethal interaction of WEE1 inhibition in H3K36me3-deficient cancer55.